Day-to-day glucose levels that stray too high when tight control is the aim, or too low when therapy isn’t intense, may signal mortality risk, an ACCORD trial subanalysis indicated.…

Boston pediatrician David Ludwig, the center of a media firestorm recently, wants to set the record straight on his view that a state should intervene in the most extreme cases of child obesity.…

Let’s forget about listing calories on menus and list the time it takes to burn the calories that you are about to order and eat. What if we listed the number of steps or the time needed to burn the calories you are about to eat rather than the calories …

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 9 to 6 against recommending the approval of the first in class novel antidiabetic agent dapagliflozin, largely because of fears that the product may cause breast and bladder cancer.… The EMDAC panel was also concerned about a lack of pharmacokinetic …

Obesity is a recognized risk factor for heart disease, but it is the location of fat — in the belly or in the liver — that combines to drive metabolic defects that produce hypertriglyceridemia, researchers found.…

This week we finish our analysis of our GLP-1 survey results with a look at prescribing reasons and habits, and how your colleagues decide on GLP-1 analog or DPP-4 inhibitor therapy. Most of the respondents favored Victoza but not as by as wide a margin as expected. Prescribers had a more …

If you do enough interviews you are bound to get a few great ones. Often when we talk to researchers they either hold back on information that they are afraid to share or they try to be experts on everything we ask them. Our publisher, Steve Freed, had a chance …

What are the effects of using a GLP-1 drug when on the Atkins diet and a low-fat diet? Who are the best candidates for using a GLP-1 drug? Can GLP-1 drugs reduce apoptosis and increase betacell regeneration? Our publisher, Steve Freed, asks these questions and much more of Dr. David …

Misconceptions abound when it come to diabetes, and this week’s Clinical Mastery Newsletter looks at a couple of them. Our Clinical Case Study looks at the reasons why telling patients that they are “borderline” may not be a good idea and our Diabetes Disaster Averted points out the problems that …

Edited by Trisha Dunning AM, RN, MEd, PhD, CDE, FRCNA and Glenn Ward MBBS, BSc, DPhil (Oxon), FRACP, FRCPath Mr.  BE was referred by a nurse working in acute care. Mr. BE is a 78-year-old male who had lithotripsy yesterday. He had an incidental random glucose 12.8 BGLs on ward range …